Australia's medical researchers have been handed a blunt new brief to simply do more with less. The newly published 10-year National Health and Medical Research Strategy from the Australian Government Department of Health, Disability and Ageing names a problem the...
Human brain organoids have fundamentally shifted the paradigm of neurological research. By transforming human pluripotent stem cells (hPSCs) into self-organizing, three-dimensional tissues, these models provide an unprecedented window into the distinct spatial...
If you followed the headlines over the past two years, you could be forgiven for thinking animal testing in drug development is already on its way out. In December 2022, the FDA Modernization Act 2.0 removed the blanket legal requirement for animal studies to support...
Our healthcare system has built a rigorous process for generating the evidence that clinicians, researchers and pharmaceutical companies rely on. Designing studies, conducting clinical trials, analyzing data, completing regulatory review and publishing results are all...
While animal models have played a central role in safety assessment and biological research for decades, advances in cellular biology, computational modelling, and micro physiological systems are prompting scientists to explore new ways of generating human-relevant...
When the Standard Playbook Runs Out In pediatric and adult oncology alike, there is a recognizable moment when the standard treatment playbook is exhausted. For patients with rare, relapsed, or treatment-resistant cancers, guidelines built for the common case offer...
CRISPR gene editing in 2026 is no longer a technology to watch. It is a technology delivering results. Across three distinct disease areas, rare inherited conditions, haematologic and solid cancers, and autoimmune disease, clinical programmes are accumulating...
Update 29th July 2026: For the completed first-half picture, including the June listings and Nasdaq's H1 figures, see Biotech IPO 2026: From Drought to Record-Breaking Deals. The biotech IPO surge has turned 2026 into a comeback year, and one statistic captures it: in...
It seems that artificial intelligence is being proposed as an answer to what could be considered as one of the most serious problems facing the life sciences sector – the problem of information overload. There has never been as much data, documentation, literature,...
Oncolytic virus development is gaining increasing attention in cancer immunotherapy research because of its ability to combine direct tumor cell killing with immune activation. Unlike conventional therapeutic strategies that focus on one pathway or one target,...
Radiation therapy is one of the important tools in the fight against cancer. About 50% of all cancer patients receive radiation therapy. Few modalities have had the same lasting impact across such a broad range of tumor types. In central nervous system (CNS) oncology,...
There are FDA-approved therapies on the market today that can permanently resolve a disease in a single administration, for a price of one to three million dollars. The reimbursement system responsible for covering that cost was built around medications that people...
A record year of out-licensing pulled the West's early pipeline sourcing toward Shanghai and Suzhou. The discount that started it is already being competed away. What outlasts it is a two-source model for global pharma innovation. For most of the past decade, a...
When Kailera Therapeutics priced its initial public offering on 16 April 2026, it did more than raise money. The Kailera Therapeutics IPO set a new benchmark for an industry that had spent the better part of three years in the wilderness. Priced at $625 million, it...
Biotech has never lacked scientific innovation. What the industry continues to underestimate is how difficult it is to turn promising science into an actual therapy that reaches patients. Over the last several years, I have seen strong assets struggle for reasons...
When López-Otín and colleagues published “The Hallmarks of Aging” in Cell in 2013, they did something the field of biogerontology had quietly needed for decades: they created a framework. Nine interconnected processes, from genomic instability and telomere attrition...
The biotech M&A 2026 market has entered what many analysts are already calling a breakout year. In the first four months of 2026 alone, pharma and biotech companies have signed deals worth approximately $84 billion, and the pipeline of transactions shows no sign...
Thesis Early-stage life science development is increasingly constrained not by lack of data, but by fragmented, multi-scale evidence that resists straightforward interpretation. AI systems can assist in structuring this complexity – through literature triage,...